ReviewInternational journal of oncology2026
Role of SPAG6 in regulating physiological functions and tumorigenesis (Review).
Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The double-edged role of SPAG6 in male reproductive toxicity: pro-invasive in leukemia, protective in germ cells.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sperm‑associated antigen 6 (SPAG6) belongs to the cancer/testis antigen family. It is a microtubule‑binding protein located on chromosome 10p12.2 and it plays an important role in various physiological processes, including ciliary movement, immune synapse formation and neurodevelopment. Abnormal SPAG6 expression occurs in multiple malignancies and developmental disorders; however, its underlying molecular mechanisms in tumorigenesis, tumor progression, clinical outcomes and therapeutic response have not been presented. This review provides a comprehensive overview of the physiological functions of SPAG6 and its mechanisms in disease, with a focus on its expression profile, function and association with disease progression and treatment response in hematologic malignancies (e.g., myelodysplastic syndrome, acute myeloid leukemia and B‑cell acute lymphoblastic leukemia) and solid tumors (e.g., breast cancer, lung cancer and osteosarcoma). SPAG6 promotes tumor progression and drug resistance by attenuating the cell cycle and through epigenetic modifications and remodeling of the tumor immune microenvironment. In addition, it may serve as a diagnostic and prognostic marker for various diseases as well as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.